Premium
Chemotherapy (platinum and pemetrexed) in combination with erlotinib in non‐small cell lung cancer induces major gastrointestinal toxicity: two case reports from the FLARE / GFPC 03‐2013 study
Author(s) -
Sassier M.,
PeyroSaintPaul L.,
Clarisse B.,
Leconte A.,
Coquerel A.,
Alexandre J.,
Fedrizzi S.,
LeroyTerquem E.,
Madroszyk A.,
Gervais R.
Publication year - 2016
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12406
Subject(s) - erlotinib , pemetrexed , medicine , lung cancer , chemotherapy , oncology , epidermal growth factor receptor , gastrointestinal cancer , toxicity , docetaxel , tyrosine kinase , erlotinib hydrochloride , cisplatin , cancer , pharmacology , receptor , colorectal cancer
Summary What is known and objective A randomized phase III study was designed to assess the efficacy and safety of second‐line platinum‐based chemotherapy with or without erlotinib in non‐small cell lung cancer ( NSCLC ) with EGFR ‐activating mutation after secondary resistance to EGFR ‐ TKI s (epidermal growth factor receptor tyrosine kinase inhibitors). Case summary We report herein two of the first three patients who presented with major gastrointestinal toxicities in the experimental arm of the trial. What is new and conclusion Pending further data, it would seem safer to administer EGFR ‐ TKI s and chemotherapy sequentially rather than concomitantly.